RyboDyn, a San Diego, CA-based biotechnology company developing immunotherapies targeting the dark genome, raised $4M in Pre-Seed funding.
The round was led by Genedant Capital and SeaX Ventures, with participation from SOSV and Swell VC.
The company intends to use the funds to expand target discovery and accelerate drug development.
Led by CEO Dr. Imad Ajjawi, RyboDyn is a biotechnology company pioneering the development of immunotherapies targeting the dark genome. By leveraging RyboCypher™, a proprietary sequencing method and advanced bioinformatics platform, it is uncovering and validating previously unknown proteins and disease-specific targets. With its scalable, in-house platform for lead discovery and optimization and proprietary IP licensed from Oregon Health and Science University, it is driving a “targets-to-assets” approach to therapeutic development.
The company collaborates with clinical and academic institutions as well as biopharma partners to validate and advance its drug pipeline, focusing on transformative solutions for cancer and other diseases with unmet medical needs.
